Evidence map›Paper›PMID 39160066›Full record

ReviewHeart (British Cardiac Society)2024

Treating iron deficiency in patients with heart failure: what, why, when, how, where and who.

Fraser J Graham, Kaushik Guha, John G Cleland, Paul R Kalra

Abstract readReview
In one paragraph

Review in Heart (British Cardiac Society), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025
    Review
  9. Article
  10. Review
  11. Diagnostics: Markers of Body Iron Status.Advances in experimental medicine and biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fraser J GrahamBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK fraser.graham@glasgow.ac.uk.ORCID 0000-0001-7539-9958
Kaushik GuhaPortsmouth Hospitals University NHS Trust, Portsmouth, UK.
John G ClelandBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK.ORCID 0000-0002-1471-7016
Paul R KalraCardiology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.ORCID 0000-0002-5288-3074

Funding

British Heart Foundation PG/2019/35089British Heart Foundation RE/18/6134217
6 · The paper itself

Abstract

For patients with heart failure and reduced or mildly reduced left ventricular ejection fraction, iron deficiency is common and associated with more severe symptoms, worse quality of life and an increased risk of hospitalisations and death. Iron deficiency can be swiftly, effectively and safely treated by administering intravenous iron, either as ferric carboxymaltose or ferric derisomaltose, which improves patient well-being and reduces the risk of hospitalisations including those for heart failure. However, the current definition of iron deficiency in heart failure has serious flaws. A serum ferritin <100 µg/L does not identify patients more likely to respond to intravenous iron. In contrast, patients with transferrin saturations <20%, most of whom are also anaemic, are more likely to have a beneficial response to intravenous iron. In this review, we summarise the available evidence for use of intravenous iron in heart failure and provide recommendations for targeted future research and practical considerations for the general cardiologist.

Indexed as

Anemia, Iron-DeficiencyHeart FailureAdministration, IntravenousFerric CompoundsFerritinsHumansIronIron DeficienciesMaltoseStroke Volumeferric carboxymaltoseFerric CompoundsFerritinsIronMaltoseBiomarkersHeart Failure, SystolicPharmacology, Clinical

Identifiers

PMID39160066
PMCPMC11503115

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.